What colistin dose in international units (IU) should be given to a 1.6 kg infant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Colistin Dosing for a 1.6 kg Infant

For a 1.6 kg infant, administer 4,000-8,000 IU (0.13-0.27 mg CBA) of colistin intravenously every 12 hours, which corresponds to 2.5-5 mg CBA/kg/day divided into 2 doses.

Dosing Calculation

The 2022 guideline from the Journal of Microbiology, Immunology and Infection provides the most recent pediatric dosing framework 1:

  • Recommended dose: 2.5-5 mg CBA/kg/day IV in 2 or 4 divided doses
  • For a 1.6 kg infant:
    • Total daily dose: 4-8 mg CBA/day
    • If divided into 2 doses (q12h): 2-4 mg CBA per dose
    • Converting to IU: 1 mg CBA = approximately 30,000 IU 2
    • Therefore: 4,000-8,000 IU per dose every 12 hours

Dosing Unit Conversion (Critical)

Pay careful attention to unit conversion to avoid dosing errors 2:

  • 1 million IU = 80 mg CMS (colistimethate sodium mass) = 33 mg CBA (colistin base activity)
  • 1 mg CBA ≈ 30,000 IU
  • Dosing should be based on colistin base activity (CBA), not CMS mass

Important Clinical Considerations

Loading Dose Controversy

The FDA and EMA recommend a loading dose of 0.15 MU/kg (approximately 150,000 IU/kg) followed by maintenance dosing 1. However, for a 1.6 kg infant, this would be 240,000 IU as a loading dose. Recent evidence suggests this may be inadequate for pathogens with MIC ≥1 mg/L 1. A 2019 randomized trial in critically ill children demonstrated improved efficacy with loading doses 3, though neonatal-specific data remains limited.

Given the very low weight and vulnerability of this patient, I recommend starting with the maintenance dose without a loading dose unless treating a life-threatening infection with documented multidrug-resistant pathogen, as neonatal safety data for loading doses is insufficient 4, 5.

Renal Function Monitoring

Monitor serum creatinine before treatment and on days 3,5, and 7 6. Nephrotoxicity occurs in 17.8-29.8% of pediatric patients, with most episodes occurring between days 3-7 of treatment 7, 8. The nephrotoxicity is typically reversible upon discontinuation 4, 8.

Combination Therapy

Colistin should always be used in combination with at least one other active antimicrobial agent (typically a carbapenem like meropenem) 1, 2. Monotherapy is associated with higher treatment failure rates and mortality.

Duration and Frequency

  • Administer every 12 hours (q12h) rather than every 6-8 hours to reduce nephrotoxicity risk while maintaining efficacy 1
  • Typical treatment duration: 10-14 days depending on infection site and clinical response
  • For neonates, the mean duration in published case series was 13.1 days (range 5-21 days) 4

Common Pitfalls to Avoid

  1. Unit confusion: Always verify whether the prescription is in IU, mg CMS, or mg CBA—these are NOT interchangeable
  2. Failure to adjust for renal impairment: Even mild renal dysfunction requires dose reduction 6
  3. Inadequate monitoring: Nephrotoxicity can develop rapidly; don't wait for routine weekly labs
  4. Monotherapy: Never use colistin alone for systemic infections
  5. Concurrent nephrotoxins: Avoid aminoglycosides, vancomycin, and amphotericin B when possible 7

Reconstitution for This Patient

Using a 150 mg (4.5 million IU) vial 6:

  • Reconstitute with 2 mL sterile water to achieve 75 mg/mL (2.25 million IU/mL)
  • For a 4,000 IU dose: withdraw 0.0018 mL (impractical—requires further dilution)
  • Practical approach: Dilute reconstituted solution further in compatible IV fluid (0.9% NaCl or D5W) to achieve measurable volumes for accurate dosing

Administer each dose as a slow IV infusion over 3-5 minutes 6.

Related Questions

What is the proper method for administering colistimethate sodium injection, and should it be diluted in normal saline?
What is the appropriate dose of colistin for a term male infant with intra‑uterine growth restriction, birth weight 1.6 kg, who is 7 days old?
What loading and maintenance doses of colistimethate sodium (colistin) should be given to an adult patient on intermittent hemodialysis?
What are the recommended guidelines, pearls, and pitfalls for intrathecal colistin administration in adult patients with confirmed or suspected multidrug‑resistant Gram‑negative meningitis or ventriculitis?
What is the recommended dose of colistin (polymyxin E) for a 3 kg neonate in the Neonatal Intensive Care Unit (NICU)?
In a patient with traumatic brain injury and chronic subdural hematomas (non‑surgical candidate) who has had watery diarrhea for 2–3 weeks and remains hypomagnesemic despite intravenous and oral magnesium replacement, what are the differential diagnoses and recommended management?
As a neurosurgery resident, what is the difference between the Br40 and Br59 reconstruction kernels for a non‑contrast head CT?
What is the appropriate dose of colistin for a term male infant with intra‑uterine growth restriction, birth weight 1.6 kg, who is 7 days old?
What are some product names of occlusive dressings for a clean, superficial, non‑contaminated wound?
In a 59-year-old male with type 2 diabetes, weight 117 kg, currently on insulin glargine (Lantus) 80 units daily and receiving continuous TPN from 8 pm to 8 am containing 300 g dextrose with 123 units of regular insulin, insulin sensitivity factor 10 mg/dL per unit, insulin‑to‑carbohydrate ratio 4 g/unit, and fasting blood glucose values of 177, 209, 226, 215, and 261 mg/dL overnight, what should the basal insulin (insulin glargine) dose and the regular insulin amount in the TPN be adjusted to?
Can dexamethasone (Dexona) injection be premixed with paracetamol for intramuscular administration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.